FDA Approves First Disease-Modifying Therapy for Children Newly Diagnosed With Stage 3 Type 1 Diabetes

The US Food and Drug Administration has granted accelerated approval to teplizumab-mzwv, marketed as Tzield, for children and adolescents aged 8 to 17 recently diagnosed with stage 3 Type 1 diabetes. The decision marks a historic milestone in pediatric endocrinology, introducing the first disease-modifying therapy for patients who have already reached the clinical stage of the disease.[1][2][3][4]

For over a century, the standard of care for clinical Type 1 diabetes has been purely reactive: replacing the insulin the pancreas can no longer produce. Tzield shifts this paradigm by targeting the underlying cause of the disease, modulating the immune system to halt its attack on the body's remaining insulin-producing beta cells.[5][7]

Type 1 diabetes develops in three distinct stages. In stage 1, the immune system begins producing autoantibodies that target pancreatic cells, but blood sugar remains normal. In stage 2, blood sugar levels become abnormal, though the patient remains asymptomatic. Stage 3 is the clinical diagnosis—the point at which symptoms like excessive thirst and fatigue appear, and the patient requires daily insulin therapy to survive.[2][4]

However, at the moment of a stage 3 diagnosis, the pancreas is not entirely depleted. Most patients still possess a fraction of functioning beta cells, entering what endocrinologists call a "honeymoon phase" where the body continues to produce a small amount of its own insulin. Preserving this residual function is the primary goal of the newly approved therapy.[3][4][7]

Tzield is a CD3-directed monoclonal antibody. It works by binding to specific T-cells—the white blood cells responsible for the autoimmune attack—and essentially reprogramming them to stand down. By interrupting this destructive process, the drug buys the surviving beta cells more time to function.[3][4][5]

The FDA's accelerated approval was anchored by data from the Phase 3 PROTECT trial, a randomized, double-blind, placebo-controlled study involving 328 children and adolescents. All participants had been diagnosed with stage 3 Type 1 diabetes within the previous six weeks.[2][3][4]

Patients in the trial received two 12-day courses of intravenous infusions—one at baseline and another at 26 weeks—alongside their standard insulin therapy. Researchers measured the drug's efficacy by tracking levels of C-peptide in the blood over a 78-week period.[2][4][5]

C-peptide is a crucial biomarker in diabetes research. Because synthetic, injected insulin does not contain C-peptide, measuring it in the bloodstream provides a highly accurate proxy for how much endogenous (natural) insulin the patient's pancreas is still producing.[2][7]

At the end of the 18-month observation period, the children who received Tzield demonstrated a significantly smaller decline in C-peptide levels compared to those who received a placebo. This statistically significant preservation of beta-cell function proved that the drug was actively slowing the progression of the disease.[2][3][4][5]

Preserving even a small amount of endogenous insulin production carries profound clinical benefits. It can lead to more stable blood glucose levels, reduce the frequency of severe hypoglycemic (low blood sugar) events, and potentially lower the risk of long-term diabetic complications such as kidney disease and neuropathy.[5][6][7]

Patient advocacy groups have heralded the approval as a transformative moment. Aaron J. Kowalski, CEO of Breakthrough T1D, noted that approximately 64,000 people are diagnosed with Type 1 diabetes annually, and this therapy finally offers a proactive option during the critical window immediately following diagnosis.[3][6]

Because this is an "accelerated approval," the FDA's decision is based on a surrogate endpoint—the C-peptide levels—which are reasonably likely to predict a clinical benefit. Sanofi is required to conduct ongoing confirmatory trials, such as the BETA-PRESERVE study, to definitively prove that these preserved C-peptide levels translate to long-term health improvements.[1][2][3][7]

The treatment is not without risks. Tzield carries a boxed warning, the FDA's most stringent safety alert, and can cause adverse reactions including lymphopenia (a drop in white blood cells), rash, vomiting, and headache. The 12-day daily IV infusion regimen also requires significant logistical coordination for families.[2][3][7]

This approval builds upon Tzield's earlier regulatory successes. The drug was first approved in November 2022 to delay the onset of stage 3 diabetes in patients with stage 2 disease. In April 2026, the FDA expanded that stage 2 indication to include children as young as one year old.[3][4]

By extending the label to include newly diagnosed stage 3 patients, regulators have bridged a critical gap in autoimmune care. While Tzield does not cure Type 1 diabetes or eliminate the need for insulin, it represents a monumental step toward managing the disease at its immunological root, rather than merely treating its symptoms.[5][6][7]